Literature DB >> 27443140

Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.

Sara Kalantari1, Mardi Gomberg-Maitland2.   

Abstract

Pulmonary hypertension is a complex disorder with multiple etiologies; the World Health Organization classification system divides pulmonary hypertension patients into 5 groups based on the underlying cause and mechanism. Group 5 pulmonary hypertension is a heterogeneous group of diseases that encompasses pulmonary hypertension secondary to multifactorial mechanisms. For many of the diseases, the true incidence, etiology, and treatment remain uncertain. This article reviews the epidemiology, pathogenesis, and management of many of the group 5 pulmonary hypertension disease states.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic thromboembolic pulmonary hypertension; Multifactorial; Pulmonary hypertension

Mesh:

Year:  2016        PMID: 27443140      PMCID: PMC5391979          DOI: 10.1016/j.ccl.2016.04.004

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  55 in total

Review 1.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

2.  Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil.

Authors:  Nils Milman; Claus Bo Svendsen; Martin Iversen; Regitze Videbaek; Jørn Carlsen
Journal:  Clin Respir J       Date:  2009-10       Impact factor: 2.570

3.  Splenectomy and chronic thromboembolic pulmonary hypertension.

Authors:  X Jaïs; V Ioos; C Jardim; O Sitbon; F Parent; A Hamid; E Fadel; P Dartevelle; G Simonneau; M Humbert
Journal:  Thorax       Date:  2005-08-05       Impact factor: 9.139

4.  Severe pulmonary hypertension in histiocytosis X.

Authors:  M Fartoukh; M Humbert; F Capron; S Maître; F Parent; C Le Gall; O Sitbon; P Hervé; P Duroux; G Simonneau
Journal:  Am J Respir Crit Care Med       Date:  2000-01       Impact factor: 21.405

5.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Authors:  Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

6.  Mortality in adults with sickle cell disease and pulmonary hypertension.

Authors:  Alem Mehari; Mark T Gladwin; Xin Tian; Roberto F Machado; Gregory J Kato
Journal:  JAMA       Date:  2012-03-28       Impact factor: 56.272

7.  Predicting mortality in patients with sarcoidosis awaiting lung transplantation.

Authors:  Andrew F Shorr; Darcy B Davies; Steven D Nathan
Journal:  Chest       Date:  2003-09       Impact factor: 9.410

8.  Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

Authors:  S Cortelazzo; G Finazzi; M Ruggeri; O Vestri; M Galli; F Rodeghiero; T Barbui
Journal:  N Engl J Med       Date:  1995-04-27       Impact factor: 91.245

9.  Clinical predictors of pulmonary hypertension in sarcoidosis.

Authors:  J M Bourbonnais; L Samavati
Journal:  Eur Respir J       Date:  2008-04-02       Impact factor: 16.671

10.  Pulmonary hypertension in chronic renal failure patients.

Authors:  Saeed Abdelwhab; Samah Elshinnawy
Journal:  Am J Nephrol       Date:  2008-07-17       Impact factor: 3.754

View more
  4 in total

Review 1.  Diagnosis and Management of Pulmonary Hypertension in Patients With CKD.

Authors:  Carl P Walther; Vijay Nambi; Nicola A Hanania; Sankar D Navaneethan
Journal:  Am J Kidney Dis       Date:  2020-03-19       Impact factor: 8.860

2.  Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances.

Authors:  Bradley A Maron; Steven H Abman; C Greg Elliott; Robert P Frantz; Rachel K Hopper; Evelyn M Horn; Mark R Nicolls; Oksana A Shlobin; Sanjiv J Shah; Gabor Kovacs; Horst Olschewski; Erika B Rosenzweig
Journal:  Am J Respir Crit Care Med       Date:  2021-06-15       Impact factor: 30.528

3.  The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension.

Authors:  Hossein Karami; Hadi Darvishi-Khezri; Mehrnoush Kosaryan; Rosetta Akbarzadeh; Mojdeh Dabirian
Journal:  Int Med Case Rep J       Date:  2018-12-17

4.  Using health administrative data to identify patients with pulmonary hypertension: A single center, proof of concept validation study in Ontario, Canada.

Authors:  Don Thiwanka Wijeratne; Ahmad Housin; Katherine Lajkosz; M Diane Lougheed; Ping Yu Xiong; David Barber; Katharine M Doliszny; Stephen L Archer
Journal:  Pulm Circ       Date:  2022-02-04       Impact factor: 2.886

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.